Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL164570 | 0.69 | ADORA3 (0.36) | ADORA3ADORA2AADORA1ADORA2BSMN1; SMN2 | |
| SCHEMBL25746214 | 0.67 | ABL1 (0.35) | ADORA3ADORA2AADORA1ADORA2BKDM4E | |
| SCHEMBL31714631 | 0.66 | ADORA2A (0.49) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL174858 | 0.66 | XDH (0.41) | ADORA3ADORA2AADORA1HTTSMN1; SMN2 | |
| SCHEMBL23399524 | 0.64 | — | — | |
| SCHEMBL29586047 | 0.63 | COMT (0.35) | ADORA3ADORA2AADORA1ADORA2BHTT | |
| SCHEMBL18359323 | 0.62 | TP53 (0.33) | ADORA3HTTSMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL20155687 | 0.61 | ATM (0.36) | ADORA3ADORA2AADORA1ADORA2BHTT | |
| SCHEMBL18083200 | 0.61 | L3MBTL1 (0.47) | HTTSMN1; SMN2ALDH1A1KDM4ENPC1 | |
| SCHEMBL20155691 | 0.60 | NPC1 (0.40) | HTTSMN1; SMN2ALDH1A1KDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130303533-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-11-14 | — | — | US | disclosed |
| EP-2611809-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012030924-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303533-A1 | AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF | JAK3, JAK2, JAK1 | ADORA3 1302/4885ADORA2A 1933/4885ADORA1 3035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.